Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Update

Dermata Therapeutics, Inc. (NASDAQ:DRMA) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 128,400 shares, a growth of 125.7% from the November 30th total of 56,900 shares. Approximately 6.4% of the shares of the stock are short sold. Based on an average trading volume of 305,000 shares, the days-to-cover ratio is currently 0.4 days.

Institutional Trading of Dermata Therapeutics

An institutional investor recently bought a new position in Dermata Therapeutics stock. Armistice Capital LLC bought a new position in shares of Dermata Therapeutics, Inc. (NASDAQ:DRMA) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 28,000 shares of the company’s stock, valued at approximately $67,000. Armistice Capital LLC owned 4.98% of Dermata Therapeutics as of its most recent SEC filing. 8.67% of the stock is currently owned by institutional investors.

Dermata Therapeutics Price Performance

Shares of NASDAQ:DRMA opened at $1.36 on Friday. The stock has a market cap of $2.77 million, a price-to-earnings ratio of -0.08 and a beta of 0.79. Dermata Therapeutics has a 12 month low of $1.00 and a 12 month high of $13.35. The stock’s 50 day moving average price is $1.26 and its 200 day moving average price is $1.76.

Dermata Therapeutics Company Profile

Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.